RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS INFECTED WITH HCV GENOTYPE 1: INTERIM RESULTS FROM THE TriCo STUDY

被引：0
|
作者：
Ferenci, P. [1 ]
Flisiak, R. [2 ]
Caruntu, F. A. [3 ]
Lengyel, G. [4 ]
Hohmann, M. [5 ]
Bakalos, G. [6 ]
机构：
[1] Med Univ Vienna, Dept Internal Med Gastroenterol & Hepatol 3, Vienna, Austria
[2] Med Univ Bialystok, Dept Infect Dis & Hepatol, Bialystok, Poland
[3] Natl Inst Infect Dis Matei Bals, Bucharest, Romania
[4] Semmelweis Univ, Dept Med 2, H-1085 Budapest, Hungary
[5] IST GmbH, Mannheim, Germany
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1123
引用
收藏
页码：S453 / S454
页数：2
相关论文
共 50 条
  • [1] Virologic response to boceprevir plus peginterferon alfa-2a (40KD) and ribavirin in treatment-naive patients with chronic hepatitis C and HCV genotype 1 infection: interim analysis of data from the international TriCo study
    Ferenci, Peter
    Flisiak, Robert
    Caruntu, Florin A.
    Lengyel, Gabriella
    Hohmann, Marc
    Tatsch, Fernando
    [J]. HEPATOLOGY, 2013, 58 : 1138A - 1139A
  • [2] HIGH SUSTAINED VIROLOGICAL RESPONSE RATES WITH RESPONSE-GUIDED DANOPREVIR PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE, HCV GENOTYPE 1 PATIENTS: ATLAS STUDY FINAL RESULTS
    Marcellin, P.
    Cooper, C.
    Balart, L. A.
    Larrey, D. G.
    Box, T. D.
    Yoshida, E.
    Lawitz, E.
    Buggisch, P.
    Ferenci, P.
    Weltman, M.
    Labriola-Tompkins, E.
    Le Pogam, S.
    Najera, I.
    Thomas, D. N.
    Hooper, G.
    Shulman, N.
    Zhang, Y.
    Navarro, M. T.
    Lim, C. Y.
    Brunda, M.
    Yetzer, E. S.
    Terrault, N.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S472 - S472
  • [3] Response-guided therapy in a prospective trial of peginterferon alfa-2a(40KD)/ribavirin treatment in patients with genotypes 1 or 4
    Ferenci, Peter
    Laferl, Hermann
    Scherzer, Thomas-Matthias
    Brunner, Harald
    Maieron, Andreas
    Gschwantler, Michael
    Stauber, Rudolf E.
    Hubmann, Rainer
    Staufer, Katharina
    Datz, Christian
    Bischof, Martin
    Hofer, Harald
    Loeschenberger, Karin
    Steindl-Munda, Petra E.
    [J]. HEPATOLOGY, 2007, 46 (04) : 814A - 815A
  • [4] Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1.
    Berg, T
    von Wagner, M
    Hinrichsen, H
    Heintges, T
    Buggisch, P
    Goeser, T
    Rasenack, J
    Pape, GR
    Schmidt, WE
    Kallinowski, B
    Klinker, H
    Spengler, U
    Klapperich, B
    Popescu, M
    Zeuzem, S
    [J]. HEPATOLOGY, 2003, 38 (04) : 317A - 317A
  • [5] RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1
    Manns, M. P.
    Poordad, F.
    Bacon, B. R.
    Bruno, S.
    Esteban, R.
    Silva, M.
    Buti, M.
    Burroughs, M.
    Sniukiene, V.
    Boparai, N.
    Brass, C. A.
    Albrecht, J. K.
    Bronowicki, J. -P.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S182 - S183
  • [6] Response-Guided Therapy With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin Reduces Treatment Duration in NaiVE and Peginterferon Alfa-2B/Ribavirin Previous-Treatment-Failure Patients With HCV Genotype 1
    Manns, Michael P.
    Poordad, Fred
    Bacon, Bruce R.
    Bruno, Savino
    Esteban, Rafael
    Silva, Marcelo O.
    Buti, Maria
    Burroughs, Margaret
    Sniukiene, Vilma
    Boparai, Navdeep
    Brass, Cliflord A.
    Albrecht, Janice K.
    Bronowicki, Jean-Pierre
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S942 - S942
  • [7] Customizing treatment with peginterferon alfa-2a (40kd) (PEGASYS®) plus ribavirin (COPEGUS®) in patients with HCV genotype 1 or 4 infection.: Interim results of a prospective randomized trial
    Ferenci, Peter
    Laferl, Herrnann
    Scherzer, Thomas-Matthias
    Maieron, Andreas
    Gschwantler, Michael
    Brunner, Henri
    Hubmann, Rainer
    Bischof, Martin
    Staufer, Katharina
    Datz, Christian
    Steindl-Munda, Petra
    Kessler, Harald
    [J]. HEPATOLOGY, 2006, 44 (04) : 336A - 336A
  • [8] RESPONSE-GUIDED THERAPY WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 OR 4: PROSPECTIVE RANDOMIZED STUDY OF EXTENDED THERAPY IN PATIENTS WITHOUT A RAPID VIROLOGICAL RESPONSE
    Ferenci, Peter
    Laferl, Hermann
    Scherzer, Thomas-Matthias
    Gschwantler, Michael
    Maieron, Andreas
    Brunner, Harald
    Stauber, Rudolf E.
    Bischol, Martin
    Bauer, Bernhard
    Datz, Christian
    Loeschenberger, Karin
    Formann, Elisabeth
    Hofer, Harald
    Steindl-Munda, Petra E.
    [J]. HEPATOLOGY, 2008, 48 (04) : 357A - 357A
  • [9] HISTOLOGIC RESPONSE TO PEGINTERFERON ALFA-2A PLUS RIBAVIRIN IN TREATMENT-NAIVE LATINO AND NON-LATINO WHITE PATIENTS INFECTED WITH HCV GENOTYPE 1: THE LATINO STUDY
    Balart, Luis A.
    Hamzeh, Fayez M.
    Rodriguez-Torres, Maribel
    [J]. HEPATOLOGY, 2008, 48 (04) : 1141A - 1141A
  • [10] Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson, David R.
    Zeuzem, Stefan
    Andreone, Pietro
    Ferenci, Peter
    Herring, Robert
    Jensen, Donald M.
    Marcellin, Patrick
    Pockros, Paul J.
    Rodriguez-Torres, Maribel
    Rossaro, Lorenzo
    Rustgi, Vinod K.
    Sepe, Thomas
    Sulkowski, Mark
    Thomason, Isaac R.
    Yoshida, Eric M.
    Chan, Anna
    Hill, George
    [J]. ANNALS OF HEPATOLOGY, 2012, 11 (01) : 15 - 31
12345